BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 10223783)

  • 1. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
    Massien C; Azizi M; Guyene TT; Vesterqvist O; Mangold B; Ménard J
    Clin Pharmacol Ther; 1999 Apr; 65(4):448-59. PubMed ID: 10223783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake.
    Azizi M; Lamarre-Cliche M; Labatide-Alanore A; Bissery A; Guyene TT; Ménard J
    J Am Soc Nephrol; 2002 Oct; 13(10):2454-63. PubMed ID: 12239234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men.
    Regamey F; Maillard M; Nussberger J; Brunner HR; Burnier M
    Hypertension; 2002 Sep; 40(3):266-72. PubMed ID: 12215465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers.
    Rousso P; Buclin T; Nussberger J; Décosterd LA; La Roche SD; Brunner-Ferber F; Brunner HR; Biollaz J
    J Hypertens; 1999 Mar; 17(3):427-37. PubMed ID: 10100082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
    Pu Q; Larouche I; Schiffrin EL
    Am J Hypertens; 2003 Nov; 16(11 Pt 1):931-7. PubMed ID: 14573331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
    Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
    Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.
    Liao WC; Vesterqvist O; Delaney C; Jemal M; Ferreira I; Ford N; Swanson B; Uderman H
    Br J Clin Pharmacol; 2003 Oct; 56(4):395-406. PubMed ID: 12968984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal and vascular effects of S21402, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, in healthy subjects with hypovolemia.
    Chodjania Y; Tharaux PL; Ragueneau I; Dussaule JC; Picker JL; Funck-Brentano C; Jaillon P
    Clin Pharmacol Ther; 2002 Jun; 71(6):468-78. PubMed ID: 12087350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
    Wallis EJ; Ramsay LE; Hettiarachchi J
    Clin Pharmacol Ther; 1998 Oct; 64(4):439-49. PubMed ID: 9797801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans.
    Azizi M; Bissery A; Peyrard S; Guyene TT; Ozoux ML; Floch A; Ménard J
    Clin Pharmacol Ther; 2006 Jan; 79(1):49-61. PubMed ID: 16413241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension.
    Maniu CV; Meyer DM; Redfield MM
    Hypertension; 2002 Oct; 40(4):528-34. PubMed ID: 12364358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
    Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
    Robl JA; Sun CQ; Stevenson J; Ryono DE; Simpkins LM; Cimarusti MP; Dejneka T; Slusarchyk WA; Chao S; Stratton L; Misra RN; Bednarz MS; Asaad MM; Cheung HS; Abboa-Offei BE; Smith PL; Mathers PD; Fox M; Schaeffer TR; Seymour AA; Trippodo NC
    J Med Chem; 1997 May; 40(11):1570-7. PubMed ID: 9171867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats.
    Cao Z; Burrell LM; Tikkanen I; Bonnet F; Cooper ME; Gilbert RE
    Kidney Int; 2001 Aug; 60(2):715-21. PubMed ID: 11473654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and Angiotensin-converting enzyme activity in humans.
    Vesterqvist O; Reeves RA
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S22-7. PubMed ID: 11716802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension.
    Favrat B; Burnier M; Nussberger J; Lecomte JM; Brouard R; Waeber B; Brunner HR
    J Hypertens; 1995 Jul; 13(7):797-804. PubMed ID: 7594444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Angiotensin-converting enzyme and neutral endopeptidase in flow-dependent remodeling.
    Korshunov VA; Massett MP; Carey RM; Berk BC
    J Vasc Res; 2004; 41(2):148-56. PubMed ID: 15004434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure.
    Chen HH; Lainchbury JG; Matsuda Y; Harty GJ; Burnett JC
    Hypertension; 2001 Aug; 38(2):187-91. PubMed ID: 11509474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
    Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
    J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure.
    Cataliotti A; Boerrigter G; Chen HH; Jougasaki M; Costello LC; Tsuruda T; Lee SC; Malatino LS; Burnett JC
    Circulation; 2002 Feb; 105(5):639-44. PubMed ID: 11827932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.